[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-mri\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-mri":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652159","non-invasive-prediction-of-early-cardiac-rejection-100652159",false,"NCT07770659","Non-invasive Prediction of EArly Cardiac rEjection","Predictive Modeling of Acute Rejection in Pediatric Heart Transplant Recipients","PEACE","Inclusion Criteria:\n\n* Received heart transplant at age \\\u003C 21 years old\n* \\> 2 months from transplant\n* ≥6 years old and ≤ 25 years old and able to undergo cardiac MRI (CMR)\n* CMR can be scheduled within 5 days from heart biopsy\\*\n* Heart catheterization with biopsy is scheduled \"for cause\" to confirm suspected AR or Heart catheterization with biopsy is scheduled for surveillance\n\nExclusion Criteria:\n\n* No endomyocardial biopsy scheduled\n* Other illness or disease process that could potentially lead to myocardial edema or fibrosis\n* Contraindication to CMR with contrast\n* Previously enrolled in this study, UNLESS previous enrollment was heart biopsy scheduled for surveillance with no suspicion of AR AND final study status was documented as \"no AR\" AND current enrollment is heart biopsy is scheduled \"for cause\" to confirm suspected AR\n* Multiple transplanted organs\n* Requires anesthesia for CMR","ALL","6 Years","25 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","Acute rejection remains a major cause of morbidity and mortality in pediatric patients after heart transplant. In order to screen for rejection, most centers perform heart catheterizations with endomyocardial biopsies frequently in the first year post transplant and then every 1-2 years thereafter; these biopsies are associated with complications, can cause significant anxiety in patients and family members, and are a significant cost for the healthcare system. This project will evaluate non-invasive methods of detecting rejection using cardiac magnetic resonance imaging and blood testing with a goal to reduce the required number of cardiac catheterizations.",[26,27,28,29,30],"Heart Transplant","Pediatric Heart Transplant","Rejection","Cardiac MRI","Cell Free DNA",[32,33,34,35,36,37],"Pediatric heart transplant","acute rejection","acute cellular rejection","antibody mediated rejection","cardiac mri","cell free DNA","RECRUITING","2026-08-17",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":42},"2023-03-29",{"date":46,"type":22},"2027-06-30",{"name":48,"class":49},"Vanderbilt University Medical Center","OTHER",22,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100639681","screening-characterization-and-longitudinal-follow-up-of-patients-with-cardiac-amyloidosis-100639681","NCT07577466","Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy\n* Presence of left ventricular wall thickness \\> 12 mm on transthoracic echocardiography and at least one \"red flag\" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)\n* Lack of written informed consent for study participation\n* Inability to comply with the study procedures","18 Years",{"count":21,"type":22},"Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months",[61,62,29,63,64,65],"Amyloidosis Cardiac","Heart Failure","Spectroscopic Analysis","Diagnosis","Phenotyping",[29,67,68,69,70,71,72,73],"Exercise MRI","Magnetic Resonace Spectroscopy","Spirometry","Cardiopulmonary Exercise Testing","Disease Progression","Treatment Monitoring","Longitudinal Study","NOT_YET_RECRUITING","2026-05-04",{"date":77,"type":42},"2026-05-11",{"date":79,"type":22},"2026-06-15",{"date":81,"type":22},"2029-12-31",{"name":83,"class":49},"Heinrich-Heine University, Duesseldorf",1]